Arcturus Q2 revenue $49.9M, net loss $17.2M; pipeline advances, Kostaive launch on track

Arcturus Therapeutics Holdings Inc.

2024-Q2 EPS reported -$1.64 revenue$87,871,000

Revenue $49.9M, up $39.4M YoY from $10.5M, driven by CSL collaboration revenue.
Net loss $17.2M ($0.64 per share) improved from $52.6M loss in Q2 2023.
Cash $317.2M; cash runway extends through Q1 2027; $437.1M received from CSL to date.
IND submitted for ARCT-032 Phase 2 cystic fibrosis study; ARCT-810 OTC deficiency interim data expected Q4 2024.
Kostaive on track for Q4 commercial launch in Japan; EMA review ongoing; COVID/flu programs with CSL progressing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.